Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform …
FPB Kroon, A Najm, A Alunno, JW Schoones… - Annals of the …, 2022 - ard.bmj.com
Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
[HTML][HTML] Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global …
JA Sparks, ZS Wallace, AM Seet… - Annals of the …, 2021 - ard.bmj.com
Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort …
Background In rituximab-treated patients with rheumatoid arthritis, humoral and cellular
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …
T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19
R Zonozi, LC Walters, A Shulkin, V Naranbhai… - Science translational …, 2023 - science.org
Individuals with primary and pharmacologic B cell deficiencies have high rates of severe
disease and mortality from coronavirus disease 2019 (COVID-19), but the immune …
disease and mortality from coronavirus disease 2019 (COVID-19), but the immune …
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
CM Denkinger, M Janssen, U Schäkel, J Gall, A Leo… - Nature Cancer, 2023 - nature.com
Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
Robust T-cell responses in anti-CD20-treated patients following COVID-19 vaccination: a prospective cohort study
N Madelon, K Lauper, G Breville… - Clinical Infectious …, 2022 - academic.oup.com
Background Patients treated with anti-CD20 therapy are particularly at risk of developing
severe coronavirus disease 2019 (COVID-19); however, little is known regarding COVID-19 …
severe coronavirus disease 2019 (COVID-19); however, little is known regarding COVID-19 …
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the …
Background The risk of severe COVID-19 outcomes in people with immune-mediated
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
Y Nguyen, A Flahault, N Chavarot, C Melenotte… - Clinical Microbiology …, 2022 - Elsevier
Objective Immunocompromised patients have an increased risk of a severe form of COVID-
19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as …
19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as …